← Back to Clinical Trials
Recruiting NCT06786468

NCT06786468 Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06786468
Status Recruiting
Phase
Sponsor Mahidol University
Condition Lung Cancer - Non Small Cell
Study Type INTERVENTIONAL
Enrollment 104 participants
Start Date 2024-04-02
Primary Completion 2026-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Early palliative care integrationStandard systemic treatment for advanced lung cancer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 104 participants in total. It began in 2024-04-02 with a primary completion date of 2026-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Early palliative care has been shown to improve the survival of advanced lung cancer patients. However, most of the clinical studies were performed in the era when systemic treatment options for this disease were limited. Currently, many effective treatment options are available, including targeted therapy and immunotherapy. These novel agents improve the treatment outcomes while having less toxicity compared to conventional chemotherapy. Moreover, medical oncologists are now trained to provide palliative care for patients. This study was designed to demonstrate whether early palliative care provided by the palliative care specialist still improves the quality of life or survival of advanced lung cancer patients compared to standard care provided by the medical oncologist.

Eligibility Criteria

Inclusion Criteria: * Age at least 18 years old * Pathologically confirmed advanced non-small cell lung cancer * Plan to receive systemic treatment for lung cancer within three weeks * ECOG performance status 0-2 with estimated life expectancy \> 24 weeks * Having at least 4 scores according to Edmonton Symptom Assessment System (ESAS) * Able to complete the questionnaires Exclusion Criteria: * Had received systemic treatment for advanced lung cancer before

Contact & Investigator

Central Contact

Lucksamon Thamlikitkul, MD, PhD

✉ lucksamon.tha@mahidol.edu

📞 +6624194489

Principal Investigator

Lucksamon Thamlikitkul, MD, PhD

PRINCIPAL INVESTIGATOR

Mahidol University

Frequently Asked Questions

Who can join the NCT06786468 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer - Non Small Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06786468 currently recruiting?

Yes, NCT06786468 is actively recruiting participants. Contact the research team at lucksamon.tha@mahidol.edu for enrollment information.

Where is the NCT06786468 trial being conducted?

This trial is being conducted at Bangkok, Thailand.

Who is sponsoring the NCT06786468 clinical trial?

NCT06786468 is sponsored by Mahidol University. The principal investigator is Lucksamon Thamlikitkul, MD, PhD at Mahidol University. The trial plans to enroll 104 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology